Drugs for Vulvovaginal Candidiasis Market

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:
Drugs for Vulvovaginal Candidiasis Market focuses on the Drugs for Vulvovaginal Candidiasis in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. Drugs for Vulvovaginal Candidiasis Market categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, Drugs for Vulvovaginal Candidiasis Market covers
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Miconazole
Clotrimazole
Fluconazole
Econazole
Other

Market Segment by Applications, can be divided into
Hospital & Clinic
Pharmacy

There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2020 and 2021;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2021;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2017 to 2022;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2017 to 2022;

Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2022 to 2028;

Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source